SG
FRTX

StoneX Group’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

StoneX Group’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-333
Closed -$1.89K – 548
2022
Q2 		$1.89K Buy
+333
New +$3.01K ﹤0.01% 501

Other funds holding FRTX

TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

StoneX Group's FRTX Position: Q3 2022 in Review

StoneX Group sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2022, closing a stake of 333 shares — an estimated $1.89K sold.

StoneX Group first reported a position in FRTX in Q2 2022 and held it in 1 quarter. The position peaked at $1.89K in Q2 2022. 17 funds tracked by Wall St. Rank hold FRTX as of Q3 2022.

  • StoneX Group reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • StoneX Group sold 333 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1.89K.
  • StoneX Group first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • StoneX Group's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.89K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.